Graft-versus-host disease
- PMID: 17438575
- DOI: 10.1038/nri2000
Graft-versus-host disease
Abstract
Allogeneic haematopoietic stem-cell transplantation (SCT) is a curative therapy for haematological malignancies and inherited disorders of blood cells, such as sickle-cell anaemia. Mature alphabeta T cells that are contained in the allografts reconstitute T-cell immunity and can eradicate malignant cells in the recipient. Unfortunately, these T cells recognize the recipient as 'non-self' and employ a wide range of immune mechanisms to attack recipient tissues in a process known as graft-versus-host disease (GVHD). The full therapeutic potential of allogeneic haematopoietic SCT will not be realized until approaches to minimize GVHD, while maintaining the positive contributions of donor T cells, are developed. This Review focuses on research in mouse models pursued to achieve this goal.
Similar articles
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review.
-
[Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].Dtsch Med Wochenschr. 2008 Jul;133(28-29):1511-6. doi: 10.1055/s-2008-1081100. Dtsch Med Wochenschr. 2008. PMID: 18597211 Review. German.
-
Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.Eur J Haematol. 2008 Sep;81(3):226-35. doi: 10.1111/j.1600-0609.2008.01108.x. Epub 2008 Jun 28. Eur J Haematol. 2008. PMID: 18573173
-
Progress and prospects: graft-versus-host disease.Gene Ther. 2010 Nov;17(11):1309-17. doi: 10.1038/gt.2010.83. Epub 2010 May 27. Gene Ther. 2010. PMID: 20508597 Review.
Cited by
-
In vivo imaging of differences in early donor cell proliferation in graft-versus-host disease hosts with different pre-conditioning doses.Mol Cells. 2012 Jan;33(1):79-86. doi: 10.1007/s10059-012-2228-y. Epub 2012 Jan 3. Mol Cells. 2012. PMID: 22228184 Free PMC article.
-
Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.J Clin Invest. 2015 Jul 1;125(7):2677-89. doi: 10.1172/JCI81229. Epub 2015 Jun 8. J Clin Invest. 2015. PMID: 26053664 Free PMC article. Clinical Trial.
-
Predicting HLA class I non-permissive amino acid residues substitutions.PLoS One. 2012;7(8):e41710. doi: 10.1371/journal.pone.0041710. Epub 2012 Aug 8. PLoS One. 2012. PMID: 22905104 Free PMC article.
-
Acute graft-versus-host disease: from the bench to the bedside.Blood. 2009 Nov 12;114(20):4327-36. doi: 10.1182/blood-2009-06-204669. Epub 2009 Aug 27. Blood. 2009. PMID: 19713461 Free PMC article. Review.
-
Inflammatory-driven NK cell maturation and its impact on pathology.Front Immunol. 2022 Dec 9;13:1061959. doi: 10.3389/fimmu.2022.1061959. eCollection 2022. Front Immunol. 2022. PMID: 36569860 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
